| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Platycodigenin targets multiple pathways involved in inflammation, cancer, and viral infection. Its anti-inflammatory activity involves the inhibition of pro-inflammatory cytokines. Its anti-cancer activity involves the induction of apoptosis in tumor cells and the inhibition of cell proliferation. Its hepatoprotective effects involve reducing oxidative stress and regulating metabolic pathways. The compound's anti-viral properties have also been reported.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Platycodigenin has anti-proliferative activity against the HSC-T6 cell line. The compound inhibits pro-inflammatory cytokines. It induces apoptosis in tumor cells and protects liver function by reducing oxidative stress and regulating metabolic pathways. Its anti-viral properties have also been reported. The compound's in vitro activity is assessed using cell proliferation assays, cytokine ELISA, and apoptosis assays.
|
| ln Vivo |
In vivo activity of Platycodigenin has not been extensively characterized in the available literature. As a natural product with anti-inflammatory, anti-cancer, and hepatoprotective properties, the compound has potential therapeutic applications. However, detailed in vivo efficacy data are not extensively reported. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro assays for Platycodigenin involve measuring its anti-proliferative, anti-inflammatory, and hepatoprotective activities. Anti-proliferative activity is assessed using cell viability assays (e.g., MTT) in cancer cell lines or HSC-T6 cells. Anti-inflammatory activity is evaluated by measuring the inhibition of pro-inflammatory cytokine production (e.g., TNF-alpha, IL-6) in stimulated macrophages using ELISA. Hepatoprotective activity is assessed in liver cell lines exposed to chemical or oxidative injury.
|
| Cell Assay |
Cellular assays for Platycodigenin are conducted to evaluate its anti-proliferative and anti-inflammatory effects. Cancer cells or HSC-T6 cells are treated with varying concentrations of the compound for 24-72 hours. Cell viability is assessed using MTT, CCK-8, or sulforhodamine B (SRB) assays. Apoptosis is evaluated by Annexin V/PI staining, caspase-3/7 activity, or TUNEL assays. Inflammatory cytokine production is measured in stimulated macrophages using ELISA. Cell cycle analysis is performed by flow cytometry.
|
| Animal Protocol |
In vivo animal studies for Platycodigenin are limited. For anti-inflammatory studies, animal models of inflammation (e.g., carrageenan-induced paw edema) could be used. For anti-cancer studies, xenograft models could be employed. For hepatoprotective studies, models of liver injury could be used. Animals would be treated with the compound via oral or intraperitoneal administration. However, specific in vivo study protocols are not extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Platycodigenin have not been extensively characterized. The compound has a molecular weight of 520.70 and a molecular formula of C30H4₈O₇. The compound is a triterpenoid with moderate lipophilicity. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported in the available literature. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Platycodigenin are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for activity studies. The compound is derived from Platycodon grandiflorum, a plant used in traditional medicine with a generally favorable safety profile. Standard safety precautions should be followed when handling this compound.
|
| Additional Infomation |
According to reports, Platycodon grandiflorus contains platycodin, and relevant data is available for reference.
Platycodigenin is a triterpenoid saponin aglycone from Platycodon grandiflorum with anti-inflammatory, anti-cancer, anti-viral, and hepatoprotective properties. It has anti-proliferative activity against HSC-T6 cells. The compound is not an FDA-approved drug and has no clinical indications. It is available in high purity (≥95%) and is typically stored at -20degC. |
| Molecular Formula |
C30H48O7
|
|---|---|
| Molecular Weight |
520.6979
|
| Exact Mass |
520.34
|
| CAS # |
22327-82-8
|
| PubChem CID |
12314399
|
| Appearance |
White to off-white solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
675.5±55.0 °C at 760 mmHg
|
| Melting Point |
242-243 °C
|
| Flash Point |
376.3±28.0 °C
|
| Vapour Pressure |
0.0±4.7 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
3.84
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
37
|
| Complexity |
986
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O([H])C1([H])[C@@]2(C(=O)O[H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[C@@]2([H])C2=C([H])C([H])([H])[C@@]3([H])[C@@]4(C([H])([H])[H])C([H])([H])C([H])(C([H])(C(C([H])([H])O[H])(C([H])([H])O[H])[C@]4([H])C([H])([H])C([H])([H])[C@@]3(C([H])([H])[H])[C@]2(C([H])([H])[H])C1([H])[H])O[H])O[H]
|
| InChi Key |
APTNOIWSCDBIAS-PCHRGASXSA-N
|
| InChi Code |
InChI=1S/C30H48O7/c1-25(2)10-11-30(24(36)37)18(12-25)17-6-7-20-26(3)13-19(33)23(35)29(15-31,16-32)21(26)8-9-27(20,4)28(17,5)14-22(30)34/h6,18-23,31-35H,7-16H2,1-5H3,(H,36,37)/t18-,19-,20+,21+,22+,23-,26+,27+,28+,30+/m0/s1
|
| Chemical Name |
(4aR,5R,6aR,6aS,6bR,8aR,10R,11S,12aR,14bS)-5,10,11-trihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~192.05 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9205 mL | 9.6025 mL | 19.2049 mL | |
| 5 mM | 0.3841 mL | 1.9205 mL | 3.8410 mL | |
| 10 mM | 0.1920 mL | 0.9602 mL | 1.9205 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
